Non-valvular atrial fibrillation (AF) carries an increased risk of stroke. Antiplatelet therapy (APT) is proven effective for stroke prevention in most patients at high-risk for vascular events, but its value for primary stroke prevention in patients with non-valvular AF merits separate consideration because of the suspected cardioembolic mechanism of most strokes in AF patients.
CITATION STYLE
Mi, A., & Hart, R. (2011). McVay et al (1998).pdf, (4).
Mendeley helps you to discover research relevant for your work.